AnaptysBio Inc (NASDAQ:ANAB) has been assigned a consensus recommendation of “Buy” from the thirteen brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $132.09.
Several research analysts have commented on the stock. Stifel Nicolaus set a $127.00 price objective on shares of AnaptysBio and gave the company a “buy” rating in a report on Sunday, November 11th. Wedbush reissued an “outperform” rating and set a $138.00 price objective on shares of AnaptysBio in a report on Tuesday, September 18th. Cantor Fitzgerald set a $124.00 target price on shares of AnaptysBio and gave the company a “buy” rating in a research note on Sunday, September 16th. Zacks Investment Research downgraded shares of AnaptysBio from a “hold” rating to a “sell” rating in a research note on Wednesday, October 17th. Finally, Credit Suisse Group set a $143.00 price objective on shares of AnaptysBio and gave the stock a “buy” rating in a research note on Friday, November 9th.
Shares of ANAB traded down $1.49 during mid-day trading on Friday, reaching $70.58. The company had a trading volume of 1,060 shares, compared to its average volume of 298,100. The stock has a market cap of $1.92 billion, a P/E ratio of -46.67 and a beta of 2.98. AnaptysBio has a 52 week low of $54.26 and a 52 week high of $134.00.
AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Thursday, November 8th. The biotechnology company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.05. The company had revenue of $5.00 million for the quarter. As a group, sell-side analysts forecast that AnaptysBio will post -2.82 EPS for the current fiscal year.
In other AnaptysBio news, insider Marco Londei sold 30,048 shares of the firm’s stock in a transaction dated Monday, December 17th. The shares were sold at an average price of $66.76, for a total transaction of $2,006,004.48. Following the completion of the transaction, the insider now directly owns 152,925 shares in the company, valued at approximately $10,209,273. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Dominic Piscitelli sold 37,000 shares of AnaptysBio stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $72.14, for a total transaction of $2,669,180.00. Following the sale, the chief financial officer now owns 37,000 shares of the company’s stock, valued at $2,669,180. The disclosure for this sale can be found here. In the last quarter, insiders have sold 204,948 shares of company stock valued at $14,434,287. 20.80% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ANAB. Vanguard Group Inc raised its stake in shares of AnaptysBio by 20.0% during the third quarter. Vanguard Group Inc now owns 1,851,930 shares of the biotechnology company’s stock valued at $184,767,000 after purchasing an additional 308,517 shares during the period. Federated Investors Inc. PA boosted its holdings in shares of AnaptysBio by 11.3% during the third quarter. Federated Investors Inc. PA now owns 547,000 shares of the biotechnology company’s stock valued at $54,574,000 after acquiring an additional 55,600 shares during the period. Marshall Wace LLP acquired a new position in shares of AnaptysBio during the third quarter valued at $10,862,000. Vanguard Group Inc. boosted its holdings in shares of AnaptysBio by 20.0% during the third quarter. Vanguard Group Inc. now owns 1,851,930 shares of the biotechnology company’s stock valued at $184,767,000 after acquiring an additional 308,517 shares during the period. Finally, TIAA CREF Investment Management LLC lifted its holdings in AnaptysBio by 18.8% in the third quarter. TIAA CREF Investment Management LLC now owns 48,514 shares of the biotechnology company’s stock worth $4,840,000 after purchasing an additional 7,670 shares during the period.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Recommended Story: How can you know how many shares are floating?
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.